BCAX - Bicara Therapeutics Inc. Common Stock
NEXT EARNINGS:
Mar 26, 2026
(in 30 days)
EPS Est: $-0.72
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$20.00
DETAILS
HIGH:
$28.00
LOW:
$14.00
MEDIAN:
$18.00
CONSENSUS:
$20.00
UPSIDE:
23.15%
Market Cap:
889.66M
Volume:
221,009
Avg Volume:
539,658
52 Week Range:
7.8-19.71
Sector:
Healthcare
Industry:
Biotechnology
Beta:
-0.78
Last Dividend:
$N/A
Exchange:
NASDAQ
Country:
US
Employees:
55
IPO Date:
2024-09-13
EPS (TTM):
-1.25
P/E Ratio:
-13.94
Revenue (TTM):
N/A
Total Assets:
569.20M
Total Debt:
738,000
Cash & Equiv:
489.71M
Rev Growth (5Y):
N/A
EPS Growth (5Y):
N/A
FCF Growth (5Y):
N/A
ROCE:
-14.9%
Debt/Equity:
0.00
Earnings History
| Date | EPS Actual | EPS Est | EPS Surprise | Rev Actual | Rev Est | Rev Surprise |
|---|---|---|---|---|---|---|
| 2025-11-10 | $-0.67 | $-0.55 | -21.8% | — | — | — |
| 2025-08-12 | $-0.50 | $-0.54 | +7.4% | — | — | — |
| 2025-05-13 | $-0.68 | $-0.40 | -70.0% | — | — | — |
| 2025-03-27 | $-0.39 | $-0.31 | -25.8% | — | — | — |
| 2024-11-12 | $-1.60 | $-0.46 | -247.8% | — | — | — |
| 2024-09-13 | $-0.27 | — | — | — | — | — |
| 2024-06-30 | $-0.27 | — | — | — | — | — |
| 2023-12-31 | $-0.23 | — | — | — | — | — |
| Metric | 2024 | 2023 | 2022 |
|---|---|---|---|
| Revenue | 0 | 0 | 0 |
| Net Income | (68.00M) | (51.98M) | (37.84M) |
| EPS | -1.25 | -1.00 | -0.73 |
| Total Assets | 569.20M | 233.98M | 6.70M |
| Total Debt | 738,000 | 657,000 | 0 |
| Cash & Equivalents | 489.71M | 230.44M | 4.16M |
| Operating Cash Flow | (74.75M) | (45.63M) | (32.08M) |
| Free Cash Flow | (74.82M) | (46.21M) | (32.27M) |
| FCF per Share | -1.37 | -0.89 | -0.62 |
| Book Value | 491.88M | 218.51M | (17.28M) |
| Cash & ST Investments | 489.71M | 230.44M | 4.16M |
| ROC Equity | -0.14 | -0.24 | N/A |